Your Complete Guide to Global Clinical Research and GCP Compliance
Future Trends: AI, RWE and New Business Models in Start-Up vs. Big Pharma Operating Models Future Trends: AI, RWE and New Business Models in Start-Up vs. Big Pharma Operating Models The landscape of clinical trials is undergoing a significant transformation, blending advanced technologies like artificial intelligence (AI) with real-world evidence (RWE) to reshape the operational…
Investor, Board and C-Suite Questions Around Start-Up vs. Big Pharma Operating Models—Answered Investor, Board and C-Suite Questions Around Start-Up vs. Big Pharma Operating Models—Answered Understanding the differing operating models between start-up biopharma companies and large pharmaceutical enterprises is critical for investor decisions, board strategy sessions, and C-suite planning. The nuances of these models can significantly…
Scenario Planning: Best-Case and Worst-Case Start-Up vs. Big Pharma Operating Models Outlooks In the ever-evolving landscape of clinical trials, particularly within the realms of good labs clinical trials and innovative therapies for diseases such as ovarian cancer, understanding the nuances between start-up and big pharma operating models is essential. This guide aims to equip clinical…
Vendor, Site and Partner Negotiation Tactics Driven by Start-Up vs. Big Pharma Operating Models Vendor, Site and Partner Negotiation Tactics Driven by Start-Up vs. Big Pharma Operating Models The landscape of clinical trials is increasingly influenced by the operational models adopted by pharmaceutical companies. This comprehensive guide aims to provide clinical operations, regulatory affairs, and…
KPIs, Dashboards and Scorecards to Track Start-Up vs. Big Pharma Operating Models The clinical trial landscape is evolving rapidly, driven by technological advancement and regulatory changes across the globe. Both start-ups and big pharmaceutical companies are involved in various clinical trials, including significant initiatives like metformin clinical trials, which serves as a pivotal area of…
Read More “KPIs, Dashboards and Scorecards to Track Start-Up vs. Big Pharma Operating Models” »
Linking M&A and Licensing Effects on Trials to Market Access, HTA and Payer Expectations Linking M&A and Licensing Effects on Trials to Market Access, HTA and Payer Expectations Introduction The landscape of clinical research has evolved significantly over recent years, with mergers and acquisitions (M&A) playing a pivotal role in shaping the paths of development…
High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins High-Impact M&A and Licensing Effects on Trials Strategies That Protect Trial Timelines and Margins The landscape of clinical trials is evolving rapidly, influenced significantly by mergers, acquisitions (M&A), and licensing agreements. These high-impact business strategies can profoundly affect trial planning, execution,…
M&A and Licensing Effects on Trials in Practice: Benchmarks, Case Studies and Playbooks The landscape of clinical research is constantly evolving, with mergers and acquisitions (M&A) and licensing agreements shaping the way clinical trials are conducted. This article provides a comprehensive view of how M&A and licensing impact clinical trials in practice, including benchmarks and…
How to Model M&A and Licensing Effects on Trials for Global Study Portfolios The dynamics of mergers and acquisitions (M&A) and licensing deals in the biopharmaceutical industry have far-reaching implications on clinical trials, particularly in a global context. The ability to effectively model these effects is crucial for clinical operations, regulatory affairs, and medical affairs…
Read More “How to Model M&A and Licensing Effects on Trials for Global Study Portfolios” »
M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now The dynamics of mergers and acquisitions (M&A) and licensing agreements within the pharmaceutical and biotechnology industries significantly influence clinical trial operations. Understanding these effects is crucial for clinical operations, regulatory affairs, and medical affairs professionals who navigate the complexities of drug development….
Read More “M&A and Licensing Effects on Trials: What Clinical Leaders Need to Know Now” »